Cooley advised Ambros Therapeutics, a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with high unmet medical need, on its definitive merger agreement with Werewolf Therapeutics for approximately $550 million.
In connection with the transaction, Cooley also advised Ambros Therapeutics on a concurrent private financing of $150 million from a syndicate of leading healthcare-dedicated investors co-led by RA Capital Management and Janus Henderson Investors.